SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.

亚利桑那州斯科茨代尔，2023年9月6日/PRNewswire/-成像终点（IE），全球肿瘤学试验成像领域的领导者和全球最大的成像CRO（ICRO）之一，很高兴地宣布任命Manish Sharma，医学博士担任其首席科学官。

Dr Sharma, a radiologist with over 20 years of extensive experience in clinical research, medical imaging, and data science, joins Imaging Endpoints with a proven track record of excellence. Besides having supported regulatory submission of multiple path-breaking therapies including priority review and accelerated approvals, his pioneering work in imaging data analytics and utilization of big data for reader performance and variability is industry-leading.

Sharma博士是一位在临床研究，医学成像和数据科学方面拥有20多年丰富经验的放射科医师，他加入了成像终点，并获得了卓越的良好记录。除了支持监管部门提交多种突破性疗法（包括优先审查和加速批准）之外，他在成像数据分析和利用大数据进行读者表现和可变性方面的开创性工作也是行业领先的。

He has also made significant strides in the use of AI/ML techniques, including deep learning applications in radiological imaging..

他还在使用AI/ML技术方面取得了重大进展，包括放射成像中的深度学习应用。。

'Manish's extensive expertise and innovative approach align perfectly with our vision to 'Connect Imaging to the Cure,'' said Ronald Korn, MD, PhD, Chief Medical Officer and Founder of Imaging Endpoints. 'His leadership in medical and regulatory strategy, including IND, NDA, ANDA, and 505(b)(2) submissions, will further enhance the depth and expertise of our blinded, independent, central review (BICR) services.'.

“Manish广泛的专业知识和创新方法与我们将成像与治疗联系起来的愿景完全一致，”首席医疗官兼成像终点创始人Ronald Korn博士说他在医疗和监管战略方面的领导地位，包括IND，NDA，ANDA和505（b）（2）意见书，将进一步加强我们的盲法，独立，中央审查（BICR）服务的深度和专业知识。

Dr. Sharma will oversee Medical and Scientific Affairs as well as Research and Development at Imaging Endpoints. His proven thought leadership, ability to develop and launch new services, and globally recognized expertise in clinical trial imaging will be instrumental in accelerating Imaging Endpoints' leadership, growth, and success..

Sharma博士将监督医疗和科学事务以及成像终点的研究和开发。他经过验证的思想领导力，开发和推出新服务的能力以及全球公认的临床试验成像专业知识将有助于加速成像终点的领导，发展和成功。。

'Ron Korn is recognized as the industry's leading expert for clinical trial imaging within oncology, and now with the addition of Manish Sharma, we expect the combination of their extraordinary talents to enable us to support more oncology trials and regulatory approvals than any other iCRO over the next several years,' said Doug Dean Burkett, PhD, CEO and President.

'Ron Korn被公认为该行业在肿瘤学领域进行临床试验成像的领先专家，现在随着Manish Sharma的加入，我们期望他们非凡的才能结合起来，使我们能够支持比任何其他肿瘤学试验和监管部门批准更多的肿瘤学试验。未来几年的iCRO，“Doug Dean Burkett博士，首席执行官兼总裁说。

'Dr Sharma's deep expertise in clinical trial imaging, excellence in read quality assurance, and aptitude for advances in data analytics will help us continue to set new standards for excellence as the preferred iCRO partner for biopharma companies across the globe.'.

“Sharma博士在临床试验成像，卓越的阅读质量保证以及数据分析能力方面的丰富专业知识将帮助我们继续为卓越设定新标准，成为全球生物制药公司的首选ICO合作伙伴。”。

'Joining Imaging Endpoints is an exciting opportunity to contribute to a leading team that shares my passion for connecting imaging with therapeutic solutions,' said Dr Sharma. 'As clinical trial designs become more complex, innovation plays a crucial role in the industry to harness all available scientific information from images and metadata for the benefit of sponsors and patients.

Sharma博士说：“加入成像终点是一个令人兴奋的机会，可以为一个领先的团队做出贡献，这个团队分享我将成像与治疗方案联系起来的激情。”随着临床试验设计变得更加复杂，创新在行业中发挥着至关重要的作用，可以利用图像和元数据中的所有可用科学信息，为赞助商和患者带来利益。

Through novel methodologies and a commitment to pushing boundaries, I look forward to leveraging my experience to drive innovation and excellence within clinical trial imaging, and enhancing our support of the most impactful clinical trials in oncology across the globe.'.

通过新颖的方法论和突破边界的承诺，我期待利用我的经验推动临床试验成像领域的创新和卓越，并加强我们对全球肿瘤学最具影响力的临床试验的支持。

About Imaging Endpoints:

关于成像终点：

Imaging Endpoints (IE) is passionately focused on its vision to Connect Imaging to the Cure. With a flawless global inspection record and a 95% marketing authorization success rate, IE has a proven track record of supporting successful regulatory submissions across the globe. IE's commitment to quality, innovation, and excellence has positioned it as the global leader in oncology imaging.

成像终点（IE）热情地专注于其视觉，将成像与治愈联系起来。凭借完美的全球检查记录和95%的上市许可成功率，IE拥有支持全球成功监管提交的可靠记录。IE对质量，创新和卓越的承诺使其成为肿瘤成像领域的全球领导者。

IE's clients, including the largest, mid-sized, and small biopharma companies, as well as all major CROs, choose IE for its industry-leading science, quality, and execution, and its remarkable track record for success..

IE的客户，包括最大，中等和小型生物制药公司，以及所有主要的CRO，都选择IE作为行业领先的科学，质量和执行力，以及卓越的成功记录。。

Imaging Endpoints is the largest oncology-focused iCRO, with 8 offices strategically located across 6 countries including Scottsdale, AZ, Cambridge, MA; London, UK; Leiden, Netherlands; Basel, Switzerland; Hyderabad, India; and Shanghai, China.

成像终点是最大的以肿瘤学为重点的ICO，有8个办事处位于6个国家，包括亚利桑那州斯科茨代尔，马萨诸塞州剑桥市；英国伦敦；荷兰莱顿；瑞士巴塞尔；印度海得拉巴；和中国上海。

IE is an affiliate of HonorHealth, one of the largest healthcare systems nationally, and also an affiliate of Southwest Medical Imaging, Ltd. (SMIL/RadPartners), part of the largest private radiology group in the U.S.

IE是HonorHealth的分支机构，HonorHealth是全国最大的医疗保健系统之一，也是西南医学影像有限公司（SMIL/RadPartners）的分支机构，是美国最大的私人放射集团的一部分。

Logo - https://mma.prnewswire.com/media/2062364/4003496/Imaging_Endpoints_Logo.jpg

徽标-https://mma.prnewswire.com/media/2062364/4003496/Imaging_Endpoints_Logo.jpg

For further media queries, please contact: [email protected], contact no. 480.314.3070.

如需进一步的媒体查询，请联系：[电子邮件保护]，联系号480.314.3070。

SOURCE Imaging Endpoints

源成像端点